Proteomics International Laboratories Ltd

Research Proteomics International Laboratories Ltd (PIQ) on Bullrun: market cap AUD 27.29M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is AUD 27.29M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025AUD 960.39K-AUD 8.11M-AUD 6.63M100.0%-0.06AUD 11.04MAUD 277.74KAUD 13.17M
FY2024AUD 892.14K-AUD 6.38M-AUD 6.00M100.0%-0.05AUD 6.64MAUD 316.40KAUD 9.41M
FY2023AUD 730.34K-AUD 6.18M-AUD 6.91M100.0%-0.05AUD 6.03MAUD 64.09KAUD 8.38M
FY2022AUD 1.49M-AUD 4.97M-AUD 3.67M100.0%-0.05AUD 2.11Mn/aAUD 3.39M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23AUD 27.29Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 AUD.

About Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Proteomics International Laboratories Ltd's market cap?

Proteomics International Laboratories Ltd's market capitalization is AUD 27.29M.

What does Proteomics International Laboratories Ltd do?

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD).